Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antigenics receives Nasdaq delisting warning

This article was originally published in Scrip

Executive Summary

Antigenicshas received a Nasdaq warning letter informing the company that it does not have the required $50 million minimum market value of listed securities set out in the index's Marketplace Rule. The company has also failed to meet the alternative rule that requires $50 million of total assets and $50 million of total revenue for either the most recently completed fiscal year or two of the past three fiscal years. Antigenics has until December 22nd to regain compliance with the rules and must have listed securities with a market value of $50 million or more for 10 consecutive days. Antigenics did not state how it plans to regain compliance but said that if it was delisted, it might appeal against the Nasdaq's decision or apply to transfer its securities from the Nasdaq Global Market to the Capital Market.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts